Drug intelligence / Profile preview

tabun

Development stage
Unknown
Lead developer
I.G. Farben
Modality
Small Molecules
Administration
Inhalation, Topical
01

Overview

Tabun is a highly toxic organophosphate nerve agent (chemical warfare agent) first synthesized in 1936 by German chemist Gerhard Schrader while researching insecticides. It was the first of the so-called G-series nerve agents and is also known by its military designation GA. Tabun acts as an irreversible inhibitor of acetylcholinesterase (AChE), leading to accumulation of acetylcholine at synapses and neuromuscular junctions. This results in continuous stimulation of muscles and glands and can cause convulsions or death due to respiratory failure. Tabun is a clear to amber liquid with a faint fruity odor reminiscent of bitter almonds; it can be absorbed through inhalation or skin contact and is lethal even at low doses. It was produced on an industrial scale during World War II but has since been banned under the Chemical Weapons Convention[1][2][7][8].

Other names
O-ethyl N,N-dimethyl phosphoramidocyanidatePhosphoramidocyanidic acid dimethyl-, ethyl esterDimethylamidoethoxyphosphoryl cyanideEthyl dimethylamidocyanophosphateEthyl dimethylphosphoramidocyanidateDimethylaminocyanphosphorsaeureaethylesterDimethylphosphoramidocyanidic acid ethyl esterEthyl N,N-dimethylphosphoramidocyanidateEthyl N,N-dimethylamino cyanophosphateGelan ILe-100Le100Le 100Taboon ATrilon 83[10]
02

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on tabun.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tabun.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call